Since Biofrontera AG (NASDAQ:BFRA) and Syros Pharmaceuticals Inc. (NASDAQ:SYRS) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation of both companies.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera AG	N/A	0.00	N/A	-0.76	0.00
Syros Pharmaceuticals Inc.	2.05M	116.68	62.28M	-1.95	0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Biofrontera AG and Syros Pharmaceuticals Inc.

	Net Margins	Return on Equity	Return on Assets
Biofrontera AG	0.00%	0%	0%
Syros Pharmaceuticals Inc.	-3,038.05%	-63.8%	-51.9%

Institutional and Insider Ownership

Institutional investors held 2.04% of Biofrontera AG shares and 80.7% of Syros Pharmaceuticals Inc. shares. About 0.04% of Biofrontera AG’s share are held by insiders. Competitively, insiders own roughly 3.3% of Syros Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Biofrontera AG	-4.8%	5.22%	-12.46%	-8.79%	0%	3.25%
Syros Pharmaceuticals Inc.	7.69%	19.2%	-1.52%	-42.47%	-31.54%	28.19%

For the past year Biofrontera AG has weaker performance than Syros Pharmaceuticals Inc.

Summary

Biofrontera AG beats Syros Pharmaceuticals Inc. on 5 of the 9 factors.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. Its lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.